Next Article in Journal
A New Trial to Measure ABO Antibodies Using Complement-Dependent Cytotoxicity
Previous Article in Journal
The Effects of the ‘Catabolic Crisis’ on Patients’ Prolonged Immobility after COVID-19 Infection
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medicina
Volume 58
Issue 6
10.3390/medicina58060829
medicina-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Hospitalized COVID-19 Patients with Severe Acute Respiratory Syndrome: A Population-Based Registry Analysis to Assess Clinical Findings, Pharmacological Treatment and Survival

by
Eduardo Gutiérrez-Abejón
1,2,3,*,
Francisco Herrera-Gómez
1,3,4,5,6,
M. Aránzazu Pedrosa-Naudín
2,
Eduardo Tamayo
3,6,7,8 and
F. Javier Álvarez
1,3,6,9
1
Pharmacological Big Data Laboratory, Faculty of Medicine, University of Valladolid, 47005 Valladolid, Spain
2
Pharmacy Directorate, Castilla y León Health Council, 47007 Valladolid, Spain
3
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (Group CB21/13/00051), Carlos III Institute of Health, 28029 Madrid, Spain
4
Transplantation Center, Faculty of Medicine, Lausanne University Hospital & University of Lausanne, CH-1011 Lausanne, Switzerland
5
Department of Kidney Resuscitation and Acute Purification Therapies, Complejo Asistencial de Zamora, Sanidad de Castilla y León, 49022 Zamora, Spain
6
Group for Biomedical Research in Critical Care Medicine (BioCritic), Faculty of Medicine, University of Valladolid, 47005 Valladolid, Spain
7
Department of Anesthesiology, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain
8
Department of Surgery, Faculty of Medicine, University of Valladolid, 47005 Valladolid, Spain
9
CEIm, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain
*
Author to whom correspondence should be addressed.
Medicina 2022, 58(6), 829; https://doi.org/10.3390/medicina58060829
Submission received: 29 May 2022 / Revised: 17 June 2022 / Accepted: 17 June 2022 / Published: 19 June 2022
(This article belongs to the Section Pulmonology)
Browse Figures
Versions Notes

Abstract

Background and Objectives: One of the most serious clinical outcomes in hospitalized patients with COVID-19 is severe acute respiratory syndrome (SARS). The aim is to analyze pharmacological treatment, survival and the main mortality predictors. Materials and Methods: A real-world data study from COVID-19-hospitalized patients with SARS from 1 March to 31 May 2020 has been carried out. Variables such as hospital length of stay, ventilation type and clinical outcomes have been taken into account. Results: In Castile and Leon, 14.03% of the 7307 in-hospital COVID-19 patients developed SARS, with a mortality rate of 42.53%. SARS prevalence was doubled in males compared to females, and 78.54% had an age of 65 years or more. The most commonly used medicines were antibiotics (89.27%), antimalarials (68.1%) and corticosteroids (55.9%). Survival of patients developing SARS was lower compared to patients without this complication (12 vs. 13 days). The main death predictors were disseminated intravascular coagulation (DIC) (OR: 13.87) and age (>65 years) (OR: 7.35). Conclusions: Patients older than 65 years who develop DIC have a higher probability of hospital death. Tocilizumab and steroids have been linked to a lower incidence of hospital death, being the main treatment for COVID-19 hospitalized patients with SARS.
Keywords: SARS-CoV-2; COVID-19; severe acute respiratory syndrome; clinical findings; pharmacological treatment; survival SARS-CoV-2; COVID-19; severe acute respiratory syndrome; clinical findings; pharmacological treatment; survival

Share and Cite

MDPI and ACS Style

Gutiérrez-Abejón, E.; Herrera-Gómez, F.; Pedrosa-Naudín, M.A.; Tamayo, E.; Álvarez, F.J. Hospitalized COVID-19 Patients with Severe Acute Respiratory Syndrome: A Population-Based Registry Analysis to Assess Clinical Findings, Pharmacological Treatment and Survival. Medicina 2022, 58, 829. https://doi.org/10.3390/medicina58060829

AMA Style

Gutiérrez-Abejón E, Herrera-Gómez F, Pedrosa-Naudín MA, Tamayo E, Álvarez FJ. Hospitalized COVID-19 Patients with Severe Acute Respiratory Syndrome: A Population-Based Registry Analysis to Assess Clinical Findings, Pharmacological Treatment and Survival. Medicina. 2022; 58(6):829. https://doi.org/10.3390/medicina58060829

Chicago/Turabian Style

Gutiérrez-Abejón, Eduardo, Francisco Herrera-Gómez, M. Aránzazu Pedrosa-Naudín, Eduardo Tamayo, and F. Javier Álvarez. 2022. "Hospitalized COVID-19 Patients with Severe Acute Respiratory Syndrome: A Population-Based Registry Analysis to Assess Clinical Findings, Pharmacological Treatment and Survival" Medicina 58, no. 6: 829. https://doi.org/10.3390/medicina58060829

APA Style

Gutiérrez-Abejón, E., Herrera-Gómez, F., Pedrosa-Naudín, M. A., Tamayo, E., & Álvarez, F. J. (2022). Hospitalized COVID-19 Patients with Severe Acute Respiratory Syndrome: A Population-Based Registry Analysis to Assess Clinical Findings, Pharmacological Treatment and Survival. Medicina, 58(6), 829. https://doi.org/10.3390/medicina58060829

Article Metrics

Back to TopTop